# Maximal Dose of Angiotensin Converting Enzyme (ACE) Inhibitor for Treatment of Diabetic Kidney Disease

> **NCT00118976** · NA · COMPLETED · sponsor: **Steno Diabetes Center Copenhagen** · enrollment: 60 (—)

## Conditions studied

- Diabetes Mellitus, Type I
- Diabetic Nephropathy

## Interventions

- **DRUG:** Lisinopril

## Key facts

- **NCT ID:** NCT00118976
- **Lead sponsor:** Steno Diabetes Center Copenhagen
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-03
- **Primary completion:** —
- **Final completion:** 2006-09
- **Target enrollment:** 60 (—)
- **Last updated:** 2006-11-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00118976

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00118976, "Maximal Dose of Angiotensin Converting Enzyme (ACE) Inhibitor for Treatment of Diabetic Kidney Disease". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT00118976. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*